Vitrafy Life Sciences Limited (ASX: VFY) - Share Price
- Current share price for VFY : $3.500
Vitrafy Life Sciences Limited (VFY), an ASX-listed company, has developed cryopreservation technology that dramatically improves cell survival rates across multiple applications including blood platelets (>88% recovery vs >50% industry standard), cell & gene therapies (96% viability vs 70% industry minimum), aquaculture and bovine reproduction. The Company provides complete cryopreservation solutions through its managed service revenue model, utilising its FDA-registered Smart Freezing and Smart Thawing devices, integrated LifeChain software platform, and Smart Packaging systems.
VFY General Information +
| ASX Code | VFY |
| Website | http://www.vitrafy.com |
| Industry/Sector | Life Sciences Tools & Services |
| Market Cap ($M) | 218 |
| VFY Share Price | $3.500 |
| Day High | $3.530 |
| Day Low | $3.440 |
| Last Close | $3.500 |
| VFY Share Price Movement | - ( No change ) |
Prices as at 16:40, 30 Jul 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Vitrafy Life Sciences Limited (VFY) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Vitrafy Life Sciences Limited (VFY) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Vitrafy Life Sciences Limited (VFY) price-sensitive announcements
VFY - Q4 FY26 Quarterly Activities Report and Appendix 4C
Vitrafy Life Sciences Limited reported significant progress in Q4 FY26, including a $32 mi
Vitrafy Life Sciences Limited (VFY)
29 Jul 2026 | 8:29 AM
29 Jul 2026 | 8:29 AM
VFY - Vitrafy enters a partnership with Hoxworth Blood Center
Vitrafy Life Sciences Limited has entered into a strategic partnership with Hoxworth Blood
Vitrafy Life Sciences Limited (VFY)
23 Jul 2026 | 8:29 AM
23 Jul 2026 | 8:29 AM
VFY - Vitrafy Share Purchase Plan Opens - SPP Offer Booklet
Vitrafy Life Sciences Limited has announced a Share Purchase Plan (SPP) following a succes
Vitrafy Life Sciences Limited (VFY)
19 Jun 2026 | 8:20 AM
19 Jun 2026 | 8:20 AM
VFY - Vitrafy Equity Raising Presentation
Vitrafy Life Sciences Limited is raising $30 million through a non-underwritten institutio
Vitrafy Life Sciences Limited (VFY)
12 Jun 2026 | 9:33 AM
12 Jun 2026 | 9:33 AM
Vitrafy Life Sciences Limited (VFY) Recent ASX Announcements
VFY Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2025A | -$32.71 | -$73.00 | 347.20% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$10.43 | -$16.30 | 33.40% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2023A | -$7.81 | -$12.20 | 2.00% | 0.00 | 0.00 | 0.00% | 0.0% |
VFY Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | ||
| Vitrafy Life Sciences Limited (VFY) | $218M | 3.4721 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
VFY Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | 7.77 | 0.00 |
| Market | 0.32 | 12.80 | 1.12 | 0.58 |
| Sector | 0.47 | 34.10 | 2.36 | 2.36 |
VFY Directors
| Name | Position | Start Date |
|---|---|---|
| Mr Brent Michael Leslie Owens | Chief Executive Officer, Managing Director | 29 Mar 2018 |
| Ms Kathryn(Kate) Marian Munnings | Non-Executive Director | 10 Oct 2024 |
| Mr Vaughan Webber | Non-Executive Director | 30 Nov 2022 |
| Dr Jeannie(Jeannette) Joughin | Non-Executive Director | 20 Jan 2026 |
| Dr Leigh Bernard Farrell | Non-Executive Director, Non-Executive Chairman | 16 Oct 2025 |
Vitrafy Life Sciences Limited (VFY) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 9 Jul 2026 | WEBBER, Vaughan | Buy | Indirect Shares | 2,454 | $2.600 | $6,380.400 |
| 9 Jul 2026 | OWENS, Brent | Buy | Indirect Shares | 1,636 | $2.600 | $4,253.600 |
| 9 Jul 2026 | MUNNINGS, Kathryn(Kate) | Buy | Indirect Shares | 2,454 | $2.600 | $6,380.400 |
See all changes in directors' interest & trades for Vitrafy Life Sciences Limited (VFY) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
VFY Management
| Name | Position |
|---|---|
| Simon Martin | Chief Financial Officer |
| Michael Sapountzis | Company Secretary |
VFY Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Vitrafy Life Sciences Limited (VFY). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 4,126,462 (6.40%) | Ryder Capital Limited |
VFY Calendar of Events
| Date | Event |
|---|---|
| 03 February 2027 | Report (Interim) |
| 04 August 2026 | Report (Annual) |
| 04 August 2026 | Report (Prelim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
